Future direction for research in drug therapy.

29 August 2016 (15:12 - 15:30)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

4 More presentations in this session

Presentation thumbnail

State of the art in drug therapy in chronic heart failure.

Professor D. van Veldhuisen (Groningen, NL)

Presentation thumbnail

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Doctor G. Savarese (Stockholm, SE)

Abstract Slides Video

Presentation thumbnail

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Professor W. Kosmala (Wroclaw, PL)

Abstract Slides Video

Presentation thumbnail

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Doctor P. Paren (Gothenburg, SE)

Access the full session

Session thumbnail

Drug therapy in heart failure

The Event

ESC Congress 2016

29 August 2016 15:12 CET

You may be interested in

Congress Session

EHRA Consensus Paper on Antiarrhythmic Drugs (AADs)

30 March 2025

Congress Presentation

AIMHY-INFORM: Dual Therapy Arm

29 August 2025

Congress Session

New insights into cancer therapy-related cardiac dysfunction

18 May 2025

Congress Presentation

Feasibility and outcomes of tailored antiplatelet therapy at a safety-net hospital

21 March 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources